PNC Financial Services Group
RARE icon

PNC Financial Services Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

PNC Financial Services Group’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$350K Sell
10,492
-558
-5% -$13.9K ﹤0.01% 2051
2026
Q1 		$231K Buy
11,050
+4,403
+66% +$99.2K ﹤0.01% 2225
2025
Q4 		$153K Sell
6,647
-649
-9% -$21.3K ﹤0.01% 2496
2025
Q3 		$219K Buy
7,296
+4,880
+202% +$146K ﹤0.01% 2241
2025
Q2 		$87.8K Sell
2,416
-321
-12% -$11.6K ﹤0.01% 2796
2025
Q1 		$99.1K Buy
2,737
+1,911
+231% +$79.5K ﹤0.01% 2666
2024
Q4 		$34.8K Buy
826
+143
+21% +$7.09K ﹤0.01% 3287
2024
Q3 		$37.9K Buy
683
+185
+37% +$9.42K ﹤0.01% 3218
2024
Q2 		$20.5K Sell
498
-16
-3% -$683 ﹤0.01% 3468
2024
Q1 		$24K Buy
514
+341
+197% +$16.1K ﹤0.01% 3359
2023
Q4 		$8.27K Sell
173
-299
-63% -$11.6K ﹤0.01% 3795
2023
Q3 		$16.8K Buy
472
+42
+10% +$1.66K ﹤0.01% 3511
2023
Q2 		$19.8K Buy
430
+379
+743% +$17.6K ﹤0.01% 3564
2023
Q1 		$2.04K Sell
51
-176
-78% -$7.55K ﹤0.01% 4306
2022
Q4 		$10.5K Buy
227
+43
+23% +$1.69K ﹤0.01% 3761
2022
Q3 		$7K Sell
184
-20
-10% -$1.03K ﹤0.01% 3884
2022
Q2 		$12K Sell
204
-86
-30% -$5.29K ﹤0.01% 3734
2022
Q1 		$20K Buy
290
+164
+130% +$11.4K ﹤0.01% 3582
2021
Q4 		$10K Sell
126
-43
-25% -$3.5K ﹤0.01% 3792
2021
Q3 		$15K Buy
169
+31
+22% +$2.8K ﹤0.01% 3621
2021
Q2 		$14K Buy
138
+62
+82% +$6.46K ﹤0.01% 3600
2021
Q1 		$9K Buy
76
+30
+65% +$4.08K ﹤0.01% 3684
2020
Q4 		$6K Sell
46
-80
-63% -$9.49K ﹤0.01% 3686
2020
Q3 		$9K Buy
126
+36
+40% +$2.98K ﹤0.01% 3546
2020
Q2 		$7K Buy
+90
New +$5.96K ﹤0.01% 3567
2019
Q4 		– Sell
-18,921
Closed -$809K – 4078
2019
Q3 		$809K Sell
18,921
-8,069
-30% -$438K ﹤0.01% 1353
2019
Q2 		$1.72M Buy
26,990
+26,971
+141,953% +$1.72M ﹤0.01% 1070
2019
Q1 		$2K Buy
19
+3
+19% +$171 ﹤0.01% 3888
2018
Q4 		$0 Hold
16
– – ﹤0.01% 4153
2018
Q3 		$2K Buy
+16
New +$1.3K ﹤0.01% 3963
2018
Q1 		– Sell
-51
Closed -$2K – 4259
2017
Q4 		$2K Buy
+51
New +$2.5K ﹤0.01% 4018
2016
Q3 		– Sell
-200
Closed -$10K – 4218
2016
Q2 		$10K Sell
200
-7
-3% -$453 ﹤0.01% 3561
2016
Q1 		$13K Sell
207
-30
-13% -$1.96K ﹤0.01% 3456
2015
Q4 		$26K Sell
237
-196
-45% -$19.6K ﹤0.01% 3166
2015
Q3 		$42K Buy
433
+178
+70% +$20.4K ﹤0.01% 2970
2015
Q2 		$26K Buy
255
+137
+116% +$10.6K ﹤0.01% 3383
2015
Q1 		$7K Buy
+118
New +$6.55K ﹤0.01% 3921

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EHI
Eagle Health Investments Greenwich, Connecticut $603M AUM 111.06% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

PNC Financial Services Group's RARE Position: Q2 2026 in Review

PNC Financial Services Group reduced its Ultragenyx Pharmaceutical (RARE) stake by 5% in Q2 2026, selling an estimated $13.9K and leaving 10,492 shares worth $350K. The position accounts for ﹤0.01% of the portfolio, ranked #2051.

PNC Financial Services Group first reported a position in RARE in Q1 2015 and has held it in 37 quarters since. The position peaked at $1.72M in Q2 2019. 119 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • PNC Financial Services Group held 10,492 shares of Ultragenyx Pharmaceutical worth $350K as of Q2 2026.
  • PNC Financial Services Group sold 558 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $13.9K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #2051 holding.
  • PNC Financial Services Group first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and has held it in 37 quarters since.
  • PNC Financial Services Group's Ultragenyx Pharmaceutical position peaked at $1.72M in Q2 2019.
  • 119 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.